Justin Sullivan/Getty Images News Gilead Sciences (NASDAQ:GILD) shares continued gains for the eighth straight session, as ...

The Tampa Bay Times e-Newspaper is a digital replica of the printed paper seven days a week that is available to read on ...

On Friday, Gilead Sciences, Inc. (GILD) stock saw a modest uptick, ending the day at $92.46 which represents a slight increase of $0.05 or 0.05% from the prior close of $92.41. The stock opened at $92 ...

As the largest internal organ in the human body, the liver supports a wide range of responsibilities related to metabolism, ...

On the occasion of the 37th World AIDS Day, the Chinese Association of STD and AIDS Prevention and Control and China Youth ...

Gilead and Aelix first teamed up in 2018 for a clinical research collaboration agreement to investigate the vaccine.

GILD has put up a solid performance in the past six months on positive data readouts and strong quarterly results. We believe ...

Zacks Research increased their FY2024 earnings per share (EPS) estimates for Gilead Sciences in a note issued to investors on ...

Aids was first identified 40 years ago: these are the game changers that have revolutionised treatment – and the obstacles ...

Spanish HIV focused immunotherapies company AELIX Therapeutics, a spin-off of IrisCaixa, has announced the acquisition of its ...

On Wednesday, Gilead Sciences, Inc. (GILD) stock saw a modest uptick, ending the day at $92.41 which represents a slight increase of $1.06 or 1.16% from the prior close of $91.35. The stock opened at ...

RBC Capital analyst Brian Abrahams maintained a Hold rating on Gilead Sciences (GILD – Research Report) on November 25 and set a price target ...